Gerresheimers, Outlook

Gerresheimer's 2026 Outlook: A Forecast Fraught with Conditions

02.04.2026 - 00:38:02 | boerse-global.de

German packaging firm Gerresheimer issues a conditional 2026 forecast pending debt talks and a BaFin probe, as delayed audits and asset sales create uncertainty.

Gerresheimer's 2026 Outlook: A Forecast Fraught with Conditions - Foto: über boerse-global.de

The German packaging specialist Gerresheimer finds itself navigating a period of significant operational and financial uncertainty. Despite a series of unresolved challenges, the company has nonetheless issued a financial forecast for the year 2026, though it comes with substantial caveats.

A Delayed Financial Calendar Creates Uncertainty

Gerresheimer's financial reporting timeline has been disrupted. The company missed the March 31 deadline to publish its audited financial statements for 2025. This delay has triggered a cascade of postponements: the quarterly report scheduled for mid-April and the Annual General Meeting set for June 3 have both been pushed to indefinite future dates. Management now targets June 2026 as the new deadline for releasing the certified accounts, with a second external auditing firm currently reviewing prior-year accounting errors.

This absence of verified financials makes a reliable assessment of the company's earnings power exceedingly difficult for investors. The equity has suffered, with shares currently trading at €19.25, reflecting a decline of approximately 30% since the start of the year.

Liquidity Measures: Divestments and Closures

To bolster its financial position, Gerresheimer is actively pursuing asset sales and operational restructuring. A key initiative is the divestment of its US subsidiary, Centor, a process being managed by investment bank Morgan Stanley. Concurrently, the company plans to shutter its Chicago Heights glass plant by the end of 2026, shifting production capacity to facilities in Italy and India.

Should investors sell immediately? Or is it worth buying Gerresheimer?

These moves follow previously announced impairment charges of €220 to €240 million for the 2025 consolidated accounts. These write-downs primarily relate to technology and development projects at Sensile Medical AG and assets belonging to Gerresheimer Moulded Glass Chicago Inc.

A Conditional Forecast Hinges on Key Resolutions

Amid these headwinds, Gerresheimer has projected 2026 revenue of €2.3 to €2.4 billion, coupled with an adjusted EBITDA margin of 18% to 19%. However, this outlook is explicitly conditional on two critical factors.

First, the company must successfully conclude negotiations with its creditors to secure extensions on existing debt facilities. Second, the forecast depends on the outcome of ongoing investigations by the German financial regulator, BaFin. The scope of these probes has expanded and now includes an examination of leasing liabilities totaling roughly €65.5 million and capitalized development costs of €29.4 million.

Gerresheimer at a turning point? This analysis reveals what investors need to know now.

Whether this 2026 projection will hold following a complete audit, or if further financial corrections will be necessary, will only become clear when the certified financial statements are finally presented in June. For now, the forecast remains strictly provisional.

Ad

Gerresheimer Stock: New Analysis - 2 April

Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Gerresheimer analysis...

So schätzen die Börsenprofis Gerresheimers Aktien ein!

<b>So schätzen die Börsenprofis Gerresheimers Aktien ein!</b>
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
DE000A0LD6E6 | GERRESHEIMERS | boerse | 69051421 |